stockrowNovartis AG
NVS Healthcare Drug Manufacturers General
Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.
- Revenue
- +4.67%
- EPS
- −69.1%
- Free cash flow
- −17.8%
- Total debt
- +53.9%
Quarter to September 2026, against a year earlier
Follow NVS
Alert me
Novartis AG (NVS) EBITDA
Novartis AG's EBITDA for fiscal 2025 was $22.9B, up 10.9% from $20.7B in fiscal 2024. Over the twelve months to 30 September 2026 it was $22.1B. Over the past ten years it has ranged from $9.0B (fiscal 2015) to $22.9B (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 4 consecutive fiscal years. Novartis AG ranks 5th of 20 Drug Manufacturers General companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $22.9B | 10.94% |
| FY2024 | $20.7B | 13.81% |
| FY2023 | $18.2B | 21.74% |
| FY2022 | $14.9B | 27.56% |
| FY2021 | $11.7B | (28.20%) |
| FY2020 | $16.3B | 9.46% |
| FY2019 | $14.9B | 9.21% |
| FY2018 | $13.6B | (8.96%) |
| FY2017 | $15.0B | 3.59% |
| FY2016 | $14.4B | 60.89% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $5.4B | (12.51%) |
| Jun 2026 | $6.2B | 13.10% |
| Mar 2026 | $5.4B | 5.65% |
| Dec 2025 | $5.2B | (11.07%) |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ABBV AbbVie Inc. compare | $28.9B |
| JNJ Johnson & Johnson compare | $27.7B |
| NVO Novo Nordisk A/S compare | $26.5B |
| NVS Novartis AG | $22.1B |
| AZN AstraZeneca PLC compare | $21.2B |
| PFE Pfizer Inc. compare | $20.1B |
| AMGN Amgen Inc. compare | $16.5B |
| MRK Merck & Co., Inc. compare | $13.7B |
| GILD Gilead Sciences, Inc. compare | $451.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on NVS
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement